AMENDMENT TRANSMITTAL LETTER



034

Docket:

D-2947CIP

FEB 2 7 2003

application of: Donovan

Serial No.: 09/810,601

Examiner:

Kam, C.M.

Filed:

March 15, 2001

Group Art Unit:

1653

For:

COMPOSITIONS AND METHODS FOR TREATING GONADOTROPHIN RELATED

ILLNESSES

COMMISSIONER FOR PATENTS Box Sequence, P.O. Box 2327 Arlington, VA 22202

RECEIVED

Sír:

MAR 0 6 2003

Transmitted herewith is an amendment in the above-identified application.

TECH CENTER 1600/2900

- [x] Response to January 23, 2002 Office Action
- [x] Declaration Pursuant to 37 C.F.R. § 1.821(f)
- [x] Paper and computer readable copies of the Sequence Listing.
- [x] No additional fee is required.

The filing fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA		
TOTAL	25	MINUS	25			
INDEP.	4	MINUS	4			
f 1First Presentation of Multiple Dep. Claim						

[x] Any patent application processing fees under 37 CFR 1.17.

	SMALL EN	NTITY		OTHER THAN SMALL ENTITY		
	RATE	ADDIT. FEE	or	RATE	ADDIT. FEE	
	x 9			x 18		
	x 42			x 84		
	+140		or	+280		
Total Addit. Fee		Total Addit, Fee		ı		

[]	Please charge my Deposit Account No the amount of \$
[x]	The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No01-0885
	[x] Any additional filing fees required under 37 CFR 1.16.

Respectfully submitted,

Attorney for Applicant

Registration Number: 25,612

4 Venture, Suite 300 Irvine, CA 92618 phone (949) 450-1750 fax (949) 450-1764



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#12/c

Kam, C.M. 3/1/07

GAU: 1653

Examiner:

RECEIVED

MAR 0 6 2003

TECH CENTER 1600/2900

Applicant: Donovan

Serial No.: 09/810,601

Filed:

March 15, 2001

For:

COMPOSITIONS AND METHODS

FOR TREATING

GONADOTROPHIN RELATED

ILLNESSES

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

RESPONSE TO JANUARY 23, 2003 OFFICE ACTION

Dear Sir:

Please amend the above-identified application as follows:

In the Specification:

Please enter the enclosed Sequence Listing into the specification of the instant application.

Remarks

This is in response to the Examiner's communication mailed January 23, 2003. A response is due February 23, 2003. Accordingly, this response is being timely filed.